These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 24357411)
1. Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome. Ishikawa T Int J Clin Oncol; 2014 Feb; 19(1):10-5. PubMed ID: 24357411 [TBL] [Abstract][Full Text] [Related]
2. More is better: combination therapies for myelodysplastic syndromes. Ornstein MC; Mukherjee S; Sekeres MA Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727 [TBL] [Abstract][Full Text] [Related]
3. Current and future management options for myelodysplastic syndromes. Bryan J; Jabbour E; Prescott H; Garcia-Manero G; Issa JP; Kantarjian H Drugs; 2010 Jul; 70(11):1381-94. PubMed ID: 20614946 [TBL] [Abstract][Full Text] [Related]
4. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. Garcia-Manero G; Fenaux P J Clin Oncol; 2011 Feb; 29(5):516-23. PubMed ID: 21220589 [TBL] [Abstract][Full Text] [Related]
5. Digging deep into "dirty" drugs - modulation of the methylation machinery. Pleyer L; Greil R Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693 [TBL] [Abstract][Full Text] [Related]
6. Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes. Finelli C; Follo MY; Stanzani M; Parisi S; Clissa C; Mongiorgi S; Barraco M; Cocco L Curr Pharm Des; 2016; 22(16):2349-57. PubMed ID: 26960675 [TBL] [Abstract][Full Text] [Related]
7. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings. Ball B; Zeidan A; Gore SD; Prebet T Leuk Lymphoma; 2017 May; 58(5):1022-1036. PubMed ID: 27654579 [TBL] [Abstract][Full Text] [Related]
8. The role of decitabine in the treatment of myelodysplastic syndromes. Atallah E; Kantarjian H; Garcia-Manero G Expert Opin Pharmacother; 2007 Jan; 8(1):65-73. PubMed ID: 17163808 [TBL] [Abstract][Full Text] [Related]
10. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia. Šimoničová K; Janotka Ľ; Kavcová H; Sulová Z; Breier A; Messingerova L Drug Resist Updat; 2022 Mar; 61():100805. PubMed ID: 35227933 [TBL] [Abstract][Full Text] [Related]
11. Treatment of higher-risk myelodysplastic syndrome. Garcia-Manero G Semin Oncol; 2011 Oct; 38(5):673-81. PubMed ID: 21943674 [TBL] [Abstract][Full Text] [Related]
12. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome. Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797 [TBL] [Abstract][Full Text] [Related]
13. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes. Wang R; Gross CP; Maggiore RJ; Halene S; Soulos PR; Raza A; Galili N; Ma X Leuk Res; 2011 Jul; 35(7):904-8. PubMed ID: 21067809 [TBL] [Abstract][Full Text] [Related]
14. Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis. Qin Y; Kuang P; Zeng Q; Wu Y; Liu T Ann Hematol; 2019 Nov; 98(11):2523-2531. PubMed ID: 31637485 [TBL] [Abstract][Full Text] [Related]
15. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide. Loiseau C; Ali A; Itzykson R Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365 [TBL] [Abstract][Full Text] [Related]
16. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm. Merkel DG; Nagler A Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866 [TBL] [Abstract][Full Text] [Related]
18. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine. Feld J; Tremblay D; Navada SC; Silverman LR Leuk Lymphoma; 2023 Mar; 64(3):525-539. PubMed ID: 36370098 [TBL] [Abstract][Full Text] [Related]
19. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update. Joeckel TE; Lübbert M Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063 [TBL] [Abstract][Full Text] [Related]
20. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Leone G; Voso MT; Teofili L; Lübbert M Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]